Abbott investigation
This article was originally published in The Gray Sheet
Executive Summary
The U.S. Attorney's Office in Massachusetts subpoenaed Abbott Laboratories in June to retrieve information on the firm's sales and marketing of its biliary stent product (Xpert), Abbott disclosed in a July 25 filing with U.S. Securities and Exchange Commission. FDA has publicly scolded companies including Abbott, Boston Scientific and C.R. Bard for marketing the stents, intended for the bile duct, for use to treat peripheral vascular diseases (1"The Gray Sheet" March 19, 2007, p. 10). The Department of Justice is now investigating companies to determine if the marketing activities might have risen to the level of violating civil or criminal laws including the Federal False Claims Act, the Food and Drug Cosmetic Act and the Anti-Kickback Statute
You may also be interested in...
FDA Rounds Up Biliary Stent Makers On Off-label Promotion
FDA gathered biliary stent manufacturers to discuss how to prevent off-label marketing for peripheral vascular disease while it clarifies the regulatory pathway for vascular stents
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.